Log In
Print
BCIQ
Print
Print this Print this
 

Levadex, dihydroergotamine (formerly MAP0004)

  Manage Alerts
Collapse Summary General Information
Company Allergan Inc.
DescriptionDihydroergotamine (DHE) mesylate compound that agonizes the serotonin (5-HT) receptor and is delivered via Map's Tempo Inhaler
Molecular Target Serotonin (5-HT1D) receptor
Mechanism of ActionSerotonin (5-HT1D) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat acute migraine in patients with compromised lung function
Regulatory Designation

U.S. - Undisclosed Review (Treat acute migraine)

Partner

Nektar Therapeutics


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today